Aptasensors for point-of-care detection of small molecules

Research output: Contribution to journalReview articleResearchpeer review

Authors

Research Organisations

External Research Organisations

  • Technion-Israel Institute of Technology
View graph of relations

Details

Original languageEnglish
Article number108
Number of pages19
JournalBiosensors
Volume10
Issue number9
Publication statusPublished - 26 Aug 2020

Abstract

Aptamers, a group of nucleic acids which can specifically bind to a target molecule, have drawn extensive interest over the past few decades. For analytics, aptamers represent a viable alternative to gold-standard antibodies due to their oligonucleic nature combined with advantageous properties, including higher stability in harsh environments and longer shelf-life. Indeed, over the last decade, aptamers have been used in numerous bioanalytical assays and in various point-of-care testing (POCT) platforms. The latter allows for rapid on-site testing and can be performed outside a laboratory by unskilled labor. Aptamer technology for POCT is not limited just to medical diagnostics; it can be used for a range of applications, including environmental monitoring and quality control. In this review, we critically examine the use of aptamers in POCT with an emphasis on their advantages and limitations. We also examine the recent success of aptasensor technology and how these findings pave the way for the analysis of small molecules in POCT and other health-related applications. Finally, the current major limitations of aptamers are discussed, and possible approaches for overcoming these challenges are presented.

Keywords

    Aptamer, Healthcare, POCT, Point-of-care testing, Small molecules

ASJC Scopus subject areas

Cite this

Aptasensors for point-of-care detection of small molecules. / Prante, Marc; Segal, Ester; Scheper, Thomas et al.
In: Biosensors, Vol. 10, No. 9, 108, 26.08.2020.

Research output: Contribution to journalReview articleResearchpeer review

Prante, M, Segal, E, Scheper, T, Bahnemann, J & Walter, J 2020, 'Aptasensors for point-of-care detection of small molecules', Biosensors, vol. 10, no. 9, 108. https://doi.org/10.3390/bios10090108
Prante, M., Segal, E., Scheper, T., Bahnemann, J., & Walter, J. (2020). Aptasensors for point-of-care detection of small molecules. Biosensors, 10(9), Article 108. https://doi.org/10.3390/bios10090108
Prante M, Segal E, Scheper T, Bahnemann J, Walter J. Aptasensors for point-of-care detection of small molecules. Biosensors. 2020 Aug 26;10(9):108. doi: 10.3390/bios10090108
Prante, Marc ; Segal, Ester ; Scheper, Thomas et al. / Aptasensors for point-of-care detection of small molecules. In: Biosensors. 2020 ; Vol. 10, No. 9.
Download
@article{be1df59757934ca0863bfc9d9f2901f5,
title = "Aptasensors for point-of-care detection of small molecules",
abstract = "Aptamers, a group of nucleic acids which can specifically bind to a target molecule, have drawn extensive interest over the past few decades. For analytics, aptamers represent a viable alternative to gold-standard antibodies due to their oligonucleic nature combined with advantageous properties, including higher stability in harsh environments and longer shelf-life. Indeed, over the last decade, aptamers have been used in numerous bioanalytical assays and in various point-of-care testing (POCT) platforms. The latter allows for rapid on-site testing and can be performed outside a laboratory by unskilled labor. Aptamer technology for POCT is not limited just to medical diagnostics; it can be used for a range of applications, including environmental monitoring and quality control. In this review, we critically examine the use of aptamers in POCT with an emphasis on their advantages and limitations. We also examine the recent success of aptasensor technology and how these findings pave the way for the analysis of small molecules in POCT and other health-related applications. Finally, the current major limitations of aptamers are discussed, and possible approaches for overcoming these challenges are presented.",
keywords = "Aptamer, Healthcare, POCT, Point-of-care testing, Small molecules",
author = "Marc Prante and Ester Segal and Thomas Scheper and Janina Bahnemann and Johanna Walter",
note = "Funding information: This research received external funding by the DFG with the project number 279/32-2.",
year = "2020",
month = aug,
day = "26",
doi = "10.3390/bios10090108",
language = "English",
volume = "10",
number = "9",

}

Download

TY - JOUR

T1 - Aptasensors for point-of-care detection of small molecules

AU - Prante, Marc

AU - Segal, Ester

AU - Scheper, Thomas

AU - Bahnemann, Janina

AU - Walter, Johanna

N1 - Funding information: This research received external funding by the DFG with the project number 279/32-2.

PY - 2020/8/26

Y1 - 2020/8/26

N2 - Aptamers, a group of nucleic acids which can specifically bind to a target molecule, have drawn extensive interest over the past few decades. For analytics, aptamers represent a viable alternative to gold-standard antibodies due to their oligonucleic nature combined with advantageous properties, including higher stability in harsh environments and longer shelf-life. Indeed, over the last decade, aptamers have been used in numerous bioanalytical assays and in various point-of-care testing (POCT) platforms. The latter allows for rapid on-site testing and can be performed outside a laboratory by unskilled labor. Aptamer technology for POCT is not limited just to medical diagnostics; it can be used for a range of applications, including environmental monitoring and quality control. In this review, we critically examine the use of aptamers in POCT with an emphasis on their advantages and limitations. We also examine the recent success of aptasensor technology and how these findings pave the way for the analysis of small molecules in POCT and other health-related applications. Finally, the current major limitations of aptamers are discussed, and possible approaches for overcoming these challenges are presented.

AB - Aptamers, a group of nucleic acids which can specifically bind to a target molecule, have drawn extensive interest over the past few decades. For analytics, aptamers represent a viable alternative to gold-standard antibodies due to their oligonucleic nature combined with advantageous properties, including higher stability in harsh environments and longer shelf-life. Indeed, over the last decade, aptamers have been used in numerous bioanalytical assays and in various point-of-care testing (POCT) platforms. The latter allows for rapid on-site testing and can be performed outside a laboratory by unskilled labor. Aptamer technology for POCT is not limited just to medical diagnostics; it can be used for a range of applications, including environmental monitoring and quality control. In this review, we critically examine the use of aptamers in POCT with an emphasis on their advantages and limitations. We also examine the recent success of aptasensor technology and how these findings pave the way for the analysis of small molecules in POCT and other health-related applications. Finally, the current major limitations of aptamers are discussed, and possible approaches for overcoming these challenges are presented.

KW - Aptamer

KW - Healthcare

KW - POCT

KW - Point-of-care testing

KW - Small molecules

UR - http://www.scopus.com/inward/record.url?scp=85090173466&partnerID=8YFLogxK

U2 - 10.3390/bios10090108

DO - 10.3390/bios10090108

M3 - Review article

C2 - 32859075

VL - 10

JO - Biosensors

JF - Biosensors

IS - 9

M1 - 108

ER -

By the same author(s)